ATLANTA--(BUSINESS WIRE)--March 12, 2006--Investigators today reported results of the ACUITY trial of The Medicines Company's (Nasdaq: MDCO) Angiomax(R) (bivalirudin). The trial met its objectives in favor of Angiomax. The results were presented as a late-breaking trial at the American College of Cardiology Scientific Session.
